Elanco Animal Health Inc. (ELAN) announced that the U.S. Food and Drug Administration has granted approval for Zenrelia, a once-daily oral JAK inhibitor designed to manage pruritus (itching) linked with allergic dermatitis, and to control atopic dermatitis in dogs aged 12 months and older.
In comparative studies, Zenrelia demonstrated equivalent effectiveness to the leading JAK inhibitor in achieving primary endpoints. Additionally, Zenrelia achieved clinical remission of itch in 77% of dogs, compared to 53% of those treated with Apoquel.
The company has initiated the launch of Zenrelia in the U.S. and is now accepting orders, with product shipments expected to commence in the coming days.
